As filed with the Securities and Exchange Commission on August 13, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
GRI BIO, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 82-4369909 | |||||||||||||
| (State or other jurisdiction | (IRS Employer Identification No.) | |||||||||||||
| of incorporation) | ||||||||||||||
2223 Avenida de la Playa, #208
La Jolla, CA 92037
(Address of principal executive offices and zip code)
Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan
(Full titles of the plans)
W. Marc Hertz, Ph.D.
Chief Executive Officer
GRI Bio, Inc.
2223 Avenida de la Playa #208
La Jolla, CA 92037
(619) 400-1170
(Name,address, including zip code and telephone number including area code of agent for service)
With Copy to:
Adam Lenain, Esq.
Melanie Ruthrauff Levy, Esq.
Hannah L. Karraker, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
3580 Carmel Mountain Road, Suite 300
San Diego, California 92130
Tel: (858) 314-1500
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large Accelerated Filer | ☐ | Accelerated Filer | ☐ | |||||||||||
Non-Accelerated Filer | ☒ | Smaller Reporting Company | ☒ | |||||||||||
Emerging Growth Company | ☒ | |||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐
EXPLANATORY NOTE
Amended and Restated 2018 Equity Incentive Plan
This Registration Statement on Form S-8 (the “Registration Statement”) registers an additional 400,000 shares of common stock, par value $0.0001 per share (“Common Stock”), of GRI Bio, Inc. (the “Registrant”), reserved for issuance pursuant to the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the “2018 Plan”), effective August 13, 2025. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to an employee benefit plan is effective (File No. 333-255972). The information contained in the Registrant’s registration statements on Form S-8 (File Nos. 333-255972 and 333-284149) is hereby incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents, which the Registrant has filed with the Securities and Exchange Commission (the “Commission”), are incorporated herein by reference:
•The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 14, 2025;
•our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Commission on May 15, 2025;
•The Registrant’s Current Reports on Form 8-K filed with the Commission on February 11, 2025, February 19, 2025, March 11, 2025, March 17, 2025, April 2, 2025, April 15, 2025, May 5, 2025, May 15, 2025, May 23, 2025, June 26, 2025, July 31, 2025 and August 13, 2025 (except for the information furnished under Items 2.02 or 7.01 and the exhibits thereto); and
•the description of our Common Stock contained in Exhibit 4.21 of our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on March 14, 2025, and any amendment or report filed with the Commission for the purpose of updating such description.
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment that indicates that all shares of Common Stock offered hereby have been sold or which deregisters all shares of Common Stock then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.
Item 8. Exhibits.
| Exhibit No. | Description | Filed Herewith | Form | Incorporated by Reference File No. | Date Filed | |||||||||||||||||||||||||||
| 4.1 | 10-K | 001-40034 | 3/28/2024 | |||||||||||||||||||||||||||||
| 4.2 | 8-K/A | 001-40034 | 5/26/2023 | |||||||||||||||||||||||||||||
| 4.3 | S-1 | 333-249636 | 10/23/2020 | |||||||||||||||||||||||||||||
| 5.1 | X | |||||||||||||||||||||||||||||||
| 23.1 | X | |||||||||||||||||||||||||||||||
| 23.3 | X | |||||||||||||||||||||||||||||||
| 24.1 | X | |||||||||||||||||||||||||||||||
| 99.1# | 8-K | 001-40034 | 8/13/2025 | |||||||||||||||||||||||||||||
| 99.2# | S-1 | 333-249636 | 10/23/2020 | |||||||||||||||||||||||||||||
| 99.3# | S-1 | 333-249636 | 10/23/2020 | |||||||||||||||||||||||||||||
| 99.4# | X | |||||||||||||||||||||||||||||||
| 107 | X | |||||||||||||||||||||||||||||||
# Indicates management contract or compensatory plan, contract or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of La Jolla, state of California on August 13, 2025.
| GRI BIO, INC. | ||||||||
| By: | /s/ W. Marc Hertz, Ph.D. | |||||||
| W. Marc Hertz, Ph.D. | ||||||||
| President and Chief Executive Officer | ||||||||
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints each of W. Marc Hertz, Ph.D., and Leanne Kelly, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||||||||
| /s/ W. Marc Hertz, Ph.D. | President, Chief Executive Officer and Director | August 13, 2025 | ||||||||||||
| W. Marc Hertz, Ph.D. | (Principal Executive Officer) | |||||||||||||
| /s/ Leanne Kelly | Chief Financial Officer | August 13, 2025 | ||||||||||||
| Leanne Kelly | (Principal Financial and Accounting Officer) | |||||||||||||
| /s/ David Szekeres | Director, Chairperson of the Board | August 13, 2025 | ||||||||||||
| David Szekeres | ||||||||||||||
| /s/ David Baker | Director | August 13, 2025 | ||||||||||||
| David Baker | ||||||||||||||
| /s/ Roelof Rongen | Director | August 13, 2025 | ||||||||||||
| Roelof Rongen | ||||||||||||||
| /s/ Camilla V. Simpson, M.Sc. | Director | August 13, 2025 | ||||||||||||
| Camilla V. Simpson, M.Sc. | ||||||||||||||